Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T

Magnetic Resonance Imaging

Volumn 30, Issue 1, 2012, Pages 139-147

  Grabner, Günther ^a   Nöbauer, Iris ^a   Elandt, Katarzyna ^a   Kronnerwetter, Claudia ^a   Woehrer, Adelheid ^a   Marosi, Christine ^a   Prayer, Daniela ^a   Trattnig, Siegfried ^a   Preusser, Matthias ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

7 T; Antiangiogenic therapy; Susceptibility weighted imaging; Tumor

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; DOXORUBICIN; IMATINIB; IRINOTECAN; TEMOZOLOMIDE;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; AUTOPSY; BRAIN EDEMA; CANCER PATIENT; CASE STUDY; CLINICAL ARTICLE; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; MALE; NEUROIMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUSCEPTIBILITY WEIGHTED IMAGING; TUMOR BLEEDING; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 82955227499     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2011.08.004     Document Type: Article

References (30)

1. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114(2):97-109.
2. Preusser M., de Ribaupierre S, Wöhrer A., et al. Current concepts and management of glioblastoma. Ann Neurol 2011, 70(1):9-21.
3. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27(28):4733-4740.
4. Norden A.D., Young G.S., Setayesh K., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70(10):779-787.
5. Iwamoto F.M., Abrey L.E., Beal K., et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009, 73(15):1200-1206.
6. Haacke E.M., Xu Y., Cheng Y.C., Reichenbach J.R. Susceptibility weighted imaging (SWI). Magn Reson Med 2004, 52(3):612-618.
7. Grabner G., Haubenberger D., Rath J., et al. A population-specific symmetric phase model to automatically analyze susceptibility-weighted imaging (SWI) phase shifts and phase symmetry in the human brain. J Magn Reson Imaging 2010, 31(1):215-220.
8. Haacke E.M., Ayaz M., Khan A., et al. Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brain. J Magn Reson Imaging 2007, 26:256-264.
9. Haacke E.M., Cheng N.Y., House M.J., et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005, 23:1-25.
10. Xu X., Wang Q., Zhang M. Age, gender, and hemispheric differences in iron deposition in the human brain: an in vivo MRI study. NeuroImage 2008, 40:35-42.
11. Reichenbach J.R., Haacke E.M. High-resolution BOLD venographic imaging: a window into brain function. NMR Biomed 2001, 14(7-8):453-467.
12. Essig M., Reichenbach J.R., Schad L.R., Schoenberg S.O., Debus J., Kaiser W.A. High- resolution MR venography of cerebral arteriovenous malformations. Magn Reson Imaging 1999, 17(10):1417-1425.
13. Lee B.C., Vo K.D., Kido D.K., et al. MR high-resolution blood oxygenation level-dependent venography of occult (low-flow) vascular lesions. AJNR Am J Neuroradiol 1999, 20(7):1239-1242.
14. Tan I.L., van Schijndel R.A., Pouwels P.J., et al. MR venography of multiple sclerosis. AJNR Am J Neuroradiol 2000, 21(6):1039-1042.
15. Li C., Ai B., Li Y., Qi H., Wu L. Susceptibility-weighted imaging in grading brain astrocytomas. Eur J Radiol 2009, 75(1):e81-e85.
16. Rauscher A., Sedlacik J., Barth M., Haacke E.M., Reichenbach J.R. Noninvasive assessment of vascular architecture and function during modulated blood oxygenation using susceptibility weighted magnetic resonance imaging. Magn Reson Med 2005, 54(1):87-95.
17. Sedlacik J., Kutschbach C., Rauscher A., Deistung A., Reichenbach J.R. Investigation of the influence of carbon dioxide concentrations on cerebral physiology by susceptibility-weighted magnetic resonance imaging (SWI). NeuroImage 2008, 43(1):36-43.
18. Pinker K., Noebauer-Huhmann I.M., Stavrou I., et al. High-field, high-resolution, susceptibility-weighted magnetic resonance imaging: improved image quality by addition of contrast agent and higher field strength in patients with brain tumors. Neuroradiology 2008, 50(1):9-16.
19. Sehgal V., Delproposto Z., Haddar D., et al. Susceptibility-weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses. J Magn Reson Imaging 2006, 24(1):41-51.
20. Park M.J., Kim H.S., Jahng G.H., Ryu C.W., Park S.M., Kim S.Y. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high- resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging. AJNR Am J Neuroradiol 2009, 30(7):1402-1408.
21. Hori M., Mori H., Aoki S., et al. Three-dimensional susceptibility-weighted imaging at 3 T using various image analysis methods in the estimation of grading intracranial gliomas. Magn Reson Imaging 2010, 28(4):594-598.
22. Moenninghoff C., Maderwald S., Theysohn J.M., et al. Imaging of adult astrocytic brain tumours with 7 T MRI: preliminary results. European radiology 2010, 20(3):704-713.
23. Zwanenburg J.J., Hendrikse J., Visser F., Takahara T., Luijten P.R. Fluid attenuated inversion recovery (FLAIR) MRI at 7.0 tesla: comparison with 1.5 and 3.0 tesla. Eur Radiol 2010, 20(4):915-922.
24. Mainero C., Benner T., Radding A., et al. In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology 2009, 73(12):941-948.
25. Noll D.C., Nishimura D.G., Macovski A. Homodyne detection in magnetic resonance imaging. IEEE Transact Med Imaging 1991, 10:154-163.
26. Vincent R.D., Janke A., Sled J.G., Baghdadi L., Neelin P., Evans A.C. MINC 2.0: a modality independent format for multidimensional medical images 2004.
27. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7(9):987-989.
28. Jain R.K., di Tomaso E., Duda D.G., Loeffler J.S., Sorensen A.G., Batchelor T.T. Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8(8):610-622.
29. Wen P.Y., Macdonald D.R., Reardon D.A., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28(11):1963-1972.
30. Thompson E.M., Dosa E., Kraemer D.F., Neuwelt E.A. Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab. J Neurooncol 2011, 103(2):353-360.